Correction: Targeting DORIS Remission and LLDAS in SLE: A Review

Affiliations

¹ Amsterdam Rheumatology Center ARC, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centre, Amsterdam, The Netherlands. a.r.parrasanchez@amsterdamumc.nl.
² Amsterdam Rheumatology Center ARC, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
³ Sub-Faculty of Clinical and Molecular Medicine, Monash University, Clayton, VIC, Australia.
⁴ Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
⁵ NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
⁶ Global Medical Affairs, Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
⁷ Clinical Development, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
⁸ Clinical Development, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Published Erratum

Agner R Parra Sánchez et al. Rheumatol Ther. 2024 Aug.

. 2024 Aug;11(4):1059-1061.

doi: 10.1007/s40744-024-00679-w.

¹ Amsterdam Rheumatology Center ARC, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centre, Amsterdam, The Netherlands. a.r.parrasanchez@amsterdamumc.nl.
² Amsterdam Rheumatology Center ARC, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
³ Sub-Faculty of Clinical and Molecular Medicine, Monash University, Clayton, VIC, Australia.
⁴ Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
⁵ NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
⁶ Global Medical Affairs, Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
⁷ Clinical Development, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
⁸ Clinical Development, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

No abstract available

Erratum for

Targeting DORIS Remission and LLDAS in SLE: A Review.
Parra Sánchez AR, van Vollenhoven RF, Morand EF, Bruce IN, Kandane-Rathnayake R, Weiss G, Tummala R, Al-Mossawi H, Sorrentino A. Parra Sánchez AR, et al. Rheumatol Ther. 2023 Dec;10(6):1459-1477. doi: 10.1007/s40744-023-00601-w. Epub 2023 Oct 5. Rheumatol Ther. 2023. PMID: 37798595 Free PMC article. Review.